Oxycodone Depot Teva GmbH
Prolonged-release oxycodone 5 mg tablets for moderate to severe pain
Oxycodone Depot Teva GmbH is a prolonged-release tablet containing 5 mg of the opioid analgesic oxycodone hydrochloride. It is prescribed for the management of moderate to severe pain that cannot be adequately controlled with non-opioid analgesics. The depot (prolonged-release) matrix delivers oxycodone steadily over approximately 12 hours, providing consistent around-the-clock pain relief. Because it is a potent opioid with a recognized risk of addiction, abuse, dependence, and potentially fatal respiratory depression, it must be used strictly as prescribed and under close medical supervision.
Quick Facts
Key Takeaways
- Oxycodone Depot Teva GmbH 5 mg is a prolonged-release tablet typically dosed every 12 hours for sustained relief of moderate to severe pain.
- It is one of the lowest depot strengths and is often chosen for opioid-naive adults, elderly patients, or those with reduced kidney or liver function.
- Tablets must be swallowed whole — crushing, chewing, or breaking them destroys the depot mechanism and can release a fatal dose at once.
- Never combine with alcohol, benzodiazepines, or other CNS depressants because of the risk of life-threatening respiratory depression.
- Physical dependence develops with continuous use; your doctor will taper the dose gradually rather than stopping abruptly.
What Is Oxycodone Depot Teva GmbH and What Is It Used For?
Quick Answer: Oxycodone Depot Teva GmbH is a generic prolonged-release tablet formulation of oxycodone hydrochloride 5 mg, manufactured by Teva GmbH. It is prescribed for around-the-clock treatment of moderate to severe pain in adults and adolescents aged 12 years and above when non-opioid analgesics are insufficient. The 5 mg strength is commonly used as a starting dose in opioid-naive patients or for dose titration in vulnerable populations.
Oxycodone is a semi-synthetic opioid derived from thebaine, an alkaloid naturally present in the opium poppy (Papaver somniferum). It belongs to the pharmacological group of natural opium alkaloids (ATC code N02AA05) and acts primarily as a full agonist at mu-opioid receptors in the central nervous system, with additional activity at kappa and delta receptors. This receptor binding inhibits ascending pain pathways, modifies the brain's perception of and emotional response to pain, and produces a general depression of central nervous system activity.
The word “depot” in the product name refers to the prolonged-release (also called modified-release, controlled-release, or extended-release) formulation. Depot tablets use a specially engineered matrix that slowly releases the active substance into the bloodstream over approximately 12 hours after ingestion. This produces stable, long-lasting plasma concentrations and sustained analgesia, avoiding the rapid peaks and troughs associated with immediate-release opioids. For this reason, depot oxycodone is indicated for chronic or long-term pain management rather than for treating breakthrough pain, where immediate-release opioids are more appropriate.
Typical clinical indications for Oxycodone Depot Teva GmbH include chronic cancer-related pain requiring continuous opioid therapy, moderate to severe post-surgical pain that extends beyond the acute phase, palliative care situations, and certain severe chronic non-cancer pain conditions where non-opioid and weaker opioid therapies have proven inadequate. International pain guidelines, including those from the World Health Organization (WHO) analgesic ladder and the European Pain Federation (EFIC), generally reserve strong opioids such as oxycodone for step 3 of the ladder — after non-opioid (step 1) and weak opioid (step 2) analgesics have been tried.
Because Teva GmbH markets this product as a generic parallel to reference brands such as OxyContin, the active substance, pharmacokinetics, and clinical effects are therapeutically equivalent to other prolonged-release oxycodone preparations with the same strength and formulation technology. Generic medicines undergo rigorous bioequivalence testing to demonstrate the same rate and extent of absorption as the originator product, as required by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and national regulatory authorities worldwide.
Oxycodone is classified as a controlled substance in virtually every country that regulates narcotics. In the United States it is a Schedule II controlled substance, in the United Kingdom it sits under Schedule 2 of the Misuse of Drugs Regulations, and in most European Union member states it falls under the national narcotics legislation. This means that prescriptions require specific formats, are usually limited to short durations, and are subject to additional record-keeping by pharmacists. Despite these safeguards, diversion, misuse, and addiction remain important public-health concerns.
What Should You Know Before Taking Oxycodone Depot Teva GmbH?
Quick Answer: Before starting Oxycodone Depot Teva GmbH, your doctor will assess your complete medical history, current medications, and risk factors for opioid misuse. It is contraindicated in severe respiratory depression, severe chronic obstructive pulmonary disease, paralytic ileus, and known hypersensitivity. Disclose any personal or family history of substance use disorder, mental health condition, or sleep-disordered breathing before the first dose.
Contraindications
Oxycodone Depot Teva GmbH must not be used in the following situations:
- Hypersensitivity to oxycodone, other opioids, or any excipient listed in the tablet coating or core.
- Severe respiratory depression with low blood oxygen (hypoxia) and/or elevated carbon dioxide (hypercapnia).
- Severe chronic obstructive pulmonary disease (COPD) or cor pulmonale (right-sided heart failure caused by chronic lung disease).
- Severe bronchial asthma in the absence of resuscitative equipment or monitored clinical settings.
- Paralytic ileus or any condition in which gastrointestinal transit is abolished.
- Acute abdomen or delayed gastric emptying where opioid-induced bowel slowing could mask or worsen the underlying problem.
- Concomitant use of monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing such therapy.
Warnings and Precautions
Particular caution is needed, and dose adjustment or alternative therapy may be required, in the following situations:
- Elderly or debilitated patients, who are more sensitive to respiratory depression, confusion, and falls.
- Impaired lung function of any degree, including obstructive or restrictive lung disease.
- Sleep-disordered breathing, including central and obstructive sleep apnea, which opioids can worsen.
- Hepatic or renal impairment, which may prolong exposure to oxycodone and its active metabolites.
- Hypothyroidism or adrenal insufficiency (e.g., Addison's disease).
- Psychiatric illness, including depression, anxiety, or psychosis, and any history of substance use disorder (alcohol or drugs).
- Prostatic hypertrophy or any condition predisposing to urinary retention.
- Pancreatitis, cholelithiasis, or known biliary tract disease.
- Inflammatory bowel disease or other obstructive bowel conditions.
- Chronic constipation, which opioids will invariably worsen.
- Increased intracranial pressure, recent head injury, or reduced level of consciousness.
- Seizure disorders or risk factors for seizures.
- Hypotension, hypovolemia, or circulatory shock.
- Recent gastrointestinal, biliary, or pelvic surgery.
Oxycodone Depot Teva GmbH contains an opioid capable of producing dependence and substance use disorder even when used therapeutically. Risk factors include personal or family history of alcohol or drug misuse, smoking, untreated psychiatric conditions, and younger age at first exposure. Before prescribing, doctors should assess baseline risk using validated tools such as the Opioid Risk Tool or SOAPP-R, and reassess at each follow-up. Early warning signs of misuse include requesting early refills, escalating dose without authorization, obtaining opioids from multiple prescribers, or using the drug for non-pain purposes. Patients who notice any of these patterns should seek medical help immediately.
Life-threatening respiratory depression is the most serious acute risk of opioid analgesics. It is most likely during initiation of therapy, after any dose increase, in opioid-naive patients, in elderly or debilitated individuals, and in combination with other CNS depressants. Oxycodone can induce or aggravate sleep-related breathing disorders, including central sleep apnea and sleep-related hypoxemia. Report any breathing pauses observed during sleep, unexplained nighttime awakenings with breathlessness, or excessive daytime somnolence to your prescribing physician without delay.
Prolonged use of opioids, including oxycodone, can paradoxically increase sensitivity to pain — a phenomenon known as opioid-induced hyperalgesia. Increasing the dose typically does not improve symptoms and may worsen them. Tolerance (needing higher doses for the same analgesic effect) is common with chronic use. If your pain seems to be escalating despite dose increases, speak with your doctor about rotating to a different opioid or introducing non-opioid strategies rather than continuing to titrate upward.
Pregnancy and Breastfeeding
If you are pregnant, planning pregnancy, or breastfeeding, discuss the risks and benefits of Oxycodone Depot Teva GmbH with your doctor before taking any dose. Opioids cross the placenta, enter breast milk, and can affect the newborn.
Pregnancy: Use during pregnancy should be avoided whenever possible. There are insufficient human data to establish safety, and animal studies have shown reproductive toxicity. Oxycodone crosses the placenta rapidly. Prolonged use during the third trimester can lead to neonatal opioid withdrawal syndrome (NOWS), a potentially life-threatening condition in the newborn characterized by irritability, hyperactivity, abnormal sleep patterns, high-pitched crying, tremors, vomiting, diarrhea, and failure to thrive. Use in the final weeks before delivery also risks neonatal respiratory depression. Where opioid treatment is unavoidable in pregnancy, the lowest effective dose should be used for the shortest duration, with neonatal monitoring arranged in advance.
Breastfeeding: Oxycodone Depot Teva GmbH is not recommended during breastfeeding. Oxycodone and its active metabolite oxymorphone pass into breast milk and can cause respiratory depression in the nursing infant. Some mothers who are ultrarapid CYP2D6 metabolizers may produce unusually high concentrations of oxymorphone in breast milk. If opioid treatment is medically essential, breastfeeding should be discontinued for the duration of therapy and for at least 24–48 hours after the last dose.
Driving, Operating Machinery, and Cognitive Effects
Oxycodone Depot Teva GmbH can impair reaction time, alertness, coordination, and judgment, particularly at the start of therapy, after any dose change, and when combined with alcohol or other CNS depressants. Patients should not drive, operate machinery, or perform safety-critical tasks until they know how the medicine affects them personally. During stable, long-term therapy without dose changes, some patients are able to drive safely, but this determination must be individualized and made by the prescribing physician. Many jurisdictions have laws prohibiting driving under the influence of opioids; you are responsible for checking local regulations.
Use in Children Under 12 Years
The safety and efficacy of Oxycodone Depot Teva GmbH have not been established in children younger than 12 years. The prolonged-release formulation is not appropriate for this age group, and alternative strategies should be used. Adolescents aged 12 and older may be treated under specialist pediatric supervision, following adult dosing principles adjusted for body weight and opioid naivety.
How Does Oxycodone Depot Teva GmbH Interact with Other Drugs?
Quick Answer: Oxycodone Depot Teva GmbH has several clinically important drug interactions. The most dangerous are with benzodiazepines, alcohol, and other CNS depressants, which may cause fatal respiratory depression. MAO inhibitors are contraindicated; CYP3A4 inhibitors can raise oxycodone levels, and CYP3A4 inducers can reduce them. Serotonergic drugs may trigger serotonin syndrome. Always share a full medication list — including over-the-counter products, herbal supplements, and recreational substances — with your prescriber and pharmacist.
Oxycodone is metabolized in the liver by the cytochrome P450 enzymes CYP3A4 (to the inactive metabolite noroxycodone) and CYP2D6 (to the more potent active metabolite oxymorphone). Drugs that inhibit or induce either enzyme can significantly alter oxycodone plasma concentrations and clinical effect. Additionally, any agent that causes central nervous system or respiratory depression can have additive or synergistic effects with oxycodone, substantially increasing the risk of adverse outcomes.
The combination of opioids like oxycodone with benzodiazepines (e.g., diazepam, alprazolam, lorazepam, clonazepam), “Z-drugs” (zolpidem, zopiclone, zaleplon), other sedative-hypnotics, anxiolytics, general anesthetics, tricyclic antidepressants, sedating antihistamines, antipsychotics, or alcohol can cause profound sedation, respiratory depression, coma, and death. Regulatory agencies worldwide — including the FDA, EMA, and MHRA — require black-box or prominent warnings on both opioid and benzodiazepine labels. If co-prescription is unavoidable, both medications should be prescribed at the lowest effective dose for the shortest duration, and the patient and household should be educated about overdose warning signs. Consider a take-home naloxone prescription.
Major Interactions
| Drug / Drug Class | Effect | Clinical Significance |
|---|---|---|
| Benzodiazepines (diazepam, lorazepam, alprazolam, clonazepam) | Additive CNS and respiratory depression | Life-threatening. Avoid combination where possible; otherwise use lowest doses, shortest duration, and intensive monitoring. |
| MAO Inhibitors (tranylcypromine, phenelzine, moclobemide, linezolid, methylene blue) | Unpredictable, potentially severe reactions including serotonin syndrome and marked CNS excitation or depression | Contraindicated during and within 14 days of MAOI therapy. |
| Alcohol (ethanol) | Enhanced CNS depression; may accelerate release from the depot matrix in some products (dose dumping) | Must be avoided entirely. Combination can cause fatal respiratory depression and unconsciousness. |
| Strong CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir, cobicistat) | Increased oxycodone plasma concentrations (up to 1.7-fold) | Enhanced and prolonged opioid effects including respiratory depression. Consider dose reduction or alternative antifungal/antibiotic. |
| Strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital, St. John's Wort) | Substantially reduced oxycodone plasma concentrations | Loss of analgesic efficacy; dose adjustment or alternative analgesic may be required. |
| CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine) | Altered ratio of oxycodone to oxymorphone; clinical impact variable | May reduce analgesic response or modestly increase side effects. Monitor closely. |
| Serotonergic drugs (SSRIs, SNRIs, TCAs, triptans, tramadol, linezolid) | Risk of serotonin syndrome (agitation, hyperthermia, tremor, clonus, rigidity) | Be alert for emergent signs; discontinue oxycodone or the serotonergic agent if syndrome develops. |
| Other opioid analgesics (morphine, fentanyl, tramadol, codeine, buprenorphine) | Additive analgesic and adverse effects | Not usually combined. Partial agonists (buprenorphine) can precipitate withdrawal. |
Other Notable Interactions
| Drug / Drug Class | Effect | Recommendation |
|---|---|---|
| Skeletal muscle relaxants (baclofen, cyclobenzaprine, tizanidine) | Enhanced CNS and respiratory depression | Monitor carefully; consider dose reduction of both agents. |
| Sedating antihistamines (diphenhydramine, hydroxyzine, promethazine) | Increased drowsiness, psychomotor impairment, and CNS depression | Prefer non-sedating alternatives when feasible. |
| Antipsychotics and neuroleptics | Additive sedation and hypotension | Monitor blood pressure and level of consciousness. |
| Gabapentinoids (gabapentin, pregabalin) | Increased CNS depression and respiratory depression risk; evidence of elevated overdose mortality | Use lowest effective doses of each. Consider take-home naloxone. |
| Cimetidine | Mild CYP inhibition; potential for increased oxycodone exposure | Monitor for enhanced opioid effects. |
| Warfarin and other coumarin anticoagulants | Reports of altered INR in either direction | Check INR when starting or stopping oxycodone. |
| Diuretics | Opioid-induced antidiuretic effect may reduce diuretic efficacy | Monitor fluid balance and electrolytes. |
| Grapefruit and grapefruit juice | CYP3A4 inhibition can increase oxycodone plasma levels | Avoid grapefruit products during treatment. |
| Cannabis / cannabinoids | Additive sedation and psychomotor impairment | Discuss with your doctor; avoid recreational use. |
What Is the Correct Dosage of Oxycodone Depot Teva GmbH?
Quick Answer: Dosage is highly individualized. Opioid-naive adults typically start on 5–10 mg every 12 hours, with Oxycodone Depot Teva GmbH 5 mg being an appropriate choice for cautious initiation. Doses are adjusted gradually based on analgesic response, tolerability, and concurrent conditions. Depot tablets must always be swallowed whole with water; crushing, chewing, or breaking the tablet can release a potentially fatal dose of oxycodone at once.
The goal of opioid titration is to achieve acceptable pain relief with tolerable side effects at the lowest effective dose. Before starting treatment, your prescribing physician should set individualized treatment goals, review exit criteria, and schedule regular follow-up. Oxycodone Depot Teva GmbH is intended for around-the-clock analgesia; it should not be used on an as-needed basis for breakthrough pain, for which an immediate-release opioid is more appropriate.
Adults and Adolescents (12 Years and Older)
Standard Starting Regimen with the 5 mg Strength
- Opioid-naive adults: 5 mg every 12 hours (total 10 mg/day), titrated upward in 25–50% increments no more often than every 1–2 days until adequate analgesia is achieved.
- Conservative initiation: Some guidelines advise starting with 5 mg every 12 hours rather than 10 mg to minimize initial nausea, drowsiness, and dizziness, particularly in opioid-naive patients.
- Chronic non-cancer pain: Most patients achieve adequate relief with 20–40 mg per day in divided doses. Escalation beyond 50 mg morphine-equivalent daily should prompt reassessment.
- Cancer and palliative pain: Higher daily doses may be required based on the intensity of pain, prior opioid exposure, and response; titration is guided by pain scores and adverse-effect profile.
- Switching from another opioid: Use validated equianalgesic conversion tables, start at the lower end to allow for incomplete cross-tolerance, and provide immediate-release breakthrough medication as needed.
| Patient Group | Suggested Starting Dose | Typical Range | Clinical Notes |
|---|---|---|---|
| Opioid-naive adult | 5 mg every 12 hours | 10–40 mg/day | Titrate cautiously; reassess efficacy and side effects after 72 hours. |
| Opioid-tolerant adult (cancer) | Based on previous 24-hour opioid dose | Individualized; often >80 mg/day | Equianalgesic conversion required; include breakthrough strategy. |
| Adolescent (12–17 years) | 5 mg every 12 hours | Individualized | Specialist pediatric supervision recommended; observe closely for respiratory effects. |
| Elderly (over 65) or frail | 5 mg every 12 hours | Lower end of range | Higher sensitivity; higher risk of falls, delirium, constipation. |
| Mild–moderate hepatic impairment | 5 mg every 12 hours; consider 5 mg every 24 hours | Individualized | Reduced metabolism; extend dosing interval if needed. |
| Severe hepatic impairment | Avoid if possible | Specialist only | Alternative analgesics usually preferred. |
| Renal impairment (eGFR <60 mL/min) | 5 mg every 12 hours or longer interval | Individualized | Reduced clearance of oxycodone and metabolites. |
| Low body weight (<50 kg) | 5 mg every 12 hours | Lower end | Enhanced sensitivity; monitor respiratory rate. |
How to Take Oxycodone Depot Teva GmbH Tablets
Swallow each depot tablet whole with a sufficient amount of water (approximately half a glass) at regular 12-hour intervals — for example, at 08:00 and 20:00. The tablet may be taken with or without food. Do not lie down immediately after administration if you have gastroesophageal reflux symptoms. Keep doses consistent from day to day; do not take two doses closer together to “catch up” on analgesia.
The prolonged-release mechanism of Oxycodone Depot Teva GmbH depends on the tablet remaining intact as it passes through the stomach and intestine. Crushing, chewing, breaking, dissolving in water, or otherwise disrupting the tablet destroys the controlled-release matrix and releases the entire oxycodone content at once. This can produce a rapidly fatal opioid overdose. Injecting dissolved tablet material is also extremely dangerous and has been associated with tissue necrosis, infection, lung granulomas, endocarditis, pulmonary embolism, and death. If you have difficulty swallowing, contact your prescriber to discuss alternative formulations.
Missed Dose
If you miss a dose of Oxycodone Depot Teva GmbH, take it as soon as you remember, provided that at least 8 hours remain until your next scheduled dose. If less than 8 hours remain, skip the missed dose entirely and continue with your regular schedule. Do not take oxycodone more frequently than every 8 hours under any circumstances, and never take a double dose to compensate for a missed tablet. If missed doses become frequent, contact your prescriber to review the regimen.
Overdose
An oxycodone overdose is a medical emergency. Call your local emergency number (e.g., 112 in the EU, 911 in the US, 999 in the UK) immediately if an overdose is suspected. Signs and symptoms include:
- Pinpoint pupils (miosis), which may dilate later if anoxia develops
- Severely reduced or absent breathing (respiratory depression)
- Extreme drowsiness, unresponsiveness, or inability to wake up
- Floppy muscle tone
- Low blood pressure, slow pulse, and cold clammy skin
- Cyanosis (bluish color of the lips or fingertips)
- In advanced cases: pulmonary edema, circulatory collapse, coma, and death
Treatment involves prompt administration of the opioid antagonist naloxone (intranasal or intramuscular) while maintaining airway patency and supporting ventilation. Because the prolonged-release formulation releases oxycodone over 12 hours, naloxone may need to be repeated, and the patient must be observed in a monitored setting for at least 24 hours. Many countries now make take-home naloxone kits available to patients on long-term opioids and their caregivers.
What Are the Side Effects of Oxycodone Depot Teva GmbH?
Quick Answer: The most common side effects include constipation, nausea, vomiting, drowsiness, dizziness, headache, and itching. The most serious adverse effect is respiratory depression, which can be fatal, particularly in combination with alcohol or benzodiazepines. Many opioid-related side effects improve within the first week of therapy; constipation, however, is usually persistent and requires active management.
Like all medicines, Oxycodone Depot Teva GmbH can cause side effects, although not everyone will experience them. Side effects are categorized by frequency using the Council for International Organizations of Medical Sciences (CIOMS) classification, based on pooled data from clinical trials and post-marketing surveillance.
- Sudden swelling of the lips, tongue, eyelids, or throat, difficulty breathing, or widespread hives (signs of anaphylaxis)
- Very slow, shallow, or labored breathing (respiratory depression)
- Bluish color of the lips, fingers, or skin (cyanosis)
- Inability to wake a person, or extreme confusion and disorientation
- Chest pain, irregular heartbeat, or sudden fainting
- Seizures
Very Common
Affects more than 1 in 10 people
- Drowsiness or sedation — usually most intense at the start of therapy or after dose increases; often improves within a few days
- Dizziness, particularly on standing
- Headache
- Constipation — typically persistent; requires prophylactic management
- Nausea
- Vomiting
- Pruritus (itching)
Common
Affects up to 1 in 10 people
- Decreased or lost appetite (anorexia)
- Anxiety, confusion, depression, nervousness, abnormal dreams, insomnia
- Tremor, lethargy, paresthesia
- Shortness of breath, wheezing, bronchospasm, reduced cough reflex
- Abdominal pain, diarrhea, dry mouth, dyspepsia (indigestion)
- Skin rash, sweating (hyperhidrosis)
- Increased urinary frequency, urinary retention
- Asthenia (general weakness), fatigue
Uncommon
Affects up to 1 in 100 people
- Hypersensitivity reactions
- Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
- Agitation, euphoria, mood swings, hallucinations, dysphoria
- Reduced libido, erectile dysfunction, drug dependence
- Seizures (especially with pre-existing epilepsy), myoclonus, involuntary muscle contractions
- Hypoesthesia, dysarthria, syncope (fainting)
- Amnesia, migraine, taste disturbance
- Visual disturbances, altered lacrimation
- Tachycardia, palpitations
- Vasodilation
- Dysphonia, cough, pharyngitis, rhinitis
- Stomatitis, gingival inflammation, dysphagia, flatulence, eructation, ileus
- Elevated hepatic transaminases
- Dry skin
- Dysuria, impotence
- Chills, chest pain, malaise, thirst
- Peripheral edema
- Physical dependence with withdrawal on discontinuation, drug tolerance
- Accidental injury
Rare and Very Rare
Affects up to 1 in 1,000 people or fewer
- Reactivation of herpes simplex
- Lymphadenopathy
- Increased appetite, weight changes
- Orthostatic hypotension
- Melena (dark, tarry stools) or frank gastrointestinal bleeding, tooth discoloration, gingival bleeding
- Urticaria, photosensitivity
- Hematuria
- Exfoliative dermatitis (very rare)
- Aggression
- Opioid-induced hyperalgesia — paradoxical increased sensitivity to pain that does not respond to dose escalation
- Dental caries
- Sphincter of Oddi dysfunction, causing severe upper abdominal pain
- Amenorrhea or menstrual irregularities
- Anaphylaxis, angioedema
Endocrine and Hormonal Effects
Long-term opioid therapy, particularly at higher doses, can suppress the hypothalamic-pituitary-gonadal axis and the hypothalamic-pituitary-adrenal axis. This may manifest as fatigue, low energy, reduced libido, erectile dysfunction, menstrual irregularities, amenorrhea, infertility, and mood changes. Endocrine symptoms that emerge during treatment should be discussed with your doctor, who may request blood tests for testosterone, estradiol, cortisol, or ACTH and consider appropriate replacement or opioid dose reduction.
Managing Common Side Effects
Most common adverse effects can be anticipated and managed with appropriate strategies:
- Constipation: Start a prophylactic laxative regimen from day one — typically a stimulant laxative (e.g., senna, bisacodyl) with or without a stool softener. Adequate hydration, dietary fiber, and physical activity help. In refractory cases, peripherally acting mu-opioid receptor antagonists (e.g., methylnaltrexone, naldemedine, naloxegol) may be prescribed.
- Nausea and vomiting: Often improve within 3–7 days. Short-term antiemetics (e.g., metoclopramide, ondansetron, haloperidol at low dose) may be used.
- Drowsiness and sedation: Usually wane with continued use or dose stabilization. Avoid activities requiring full alertness during the adjustment period. Review co-sedating medications.
- Pruritus: Non-sedating antihistamines may help; consider opioid rotation if persistent.
- Dry mouth: Frequent sips of water, sugar-free gum or lozenges, saliva substitutes, and meticulous dental hygiene reduce the risk of caries.
- Respiratory symptoms: Any new or worsening breathlessness should prompt urgent medical review.
What Happens When You Stop Taking Oxycodone Depot Teva GmbH?
Quick Answer: Never stop Oxycodone Depot Teva GmbH abruptly after regular use. The body develops physical dependence within days to weeks, and sudden discontinuation produces a distressing opioid withdrawal syndrome. Your doctor will design an individualized tapering schedule — often reducing the daily dose by 10–25% every 1–4 weeks — to minimize withdrawal symptoms and safely bring treatment to an end.
Physical dependence and tolerance are predictable pharmacological responses to continuous opioid exposure and are distinct from addiction, which is a behavioral disorder characterized by compulsive use despite harm. Physical dependence develops in virtually everyone who takes opioids regularly for more than a few weeks, while addiction affects a minority of patients whose risk factors and biological vulnerabilities combine unfavorably.
Common symptoms of opioid withdrawal include:
- Yawning, lacrimation (watery eyes), and rhinorrhea (runny nose)
- Dilated pupils (mydriasis)
- Tremors, piloerection (goosebumps), and excessive sweating
- Restlessness, anxiety, irritability, and insomnia
- Muscle aches, abdominal cramps, joint pain, and bone pain
- Nausea, vomiting, and diarrhea
- Tachycardia, hypertension, and dysregulated temperature
- Intense drug craving
Symptom onset after the last dose of prolonged-release oxycodone is typically 12–24 hours, with peak severity around 36–72 hours and resolution of most acute physical symptoms within 7–10 days. Some patients experience protracted withdrawal symptoms, particularly insomnia, anhedonia, and low mood, that persist for weeks to months.
When opioid therapy is no longer needed, your doctor will design a gradual taper tailored to your current dose, duration of use, indication, and co-morbidities. A slower taper (e.g., 10% per month) is generally better tolerated than rapid reductions. Adjunctive medications such as alpha-2 adrenergic agonists (clonidine, lofexidine), anticonvulsants (gabapentin), antidepressants, or non-opioid analgesics may be used to support the transition. Patients who have developed opioid use disorder may benefit from specialist addiction treatment, including opioid agonist therapy with buprenorphine or methadone. Never adjust your dose on your own — always work with your prescriber.
How Should You Store Oxycodone Depot Teva GmbH?
Quick Answer: Store Oxycodone Depot Teva GmbH in a secure, locked location at or below 25°C, out of sight and reach of children, pets, and anyone to whom it has not been prescribed. Keep tablets in the original blister pack. Never dispose of unused tablets in household waste or wastewater; return them to a pharmacy or authorized take-back program.
Oxycodone Depot Teva GmbH is a controlled substance and represents a serious risk of accidental or intentional harm if it is diverted from its intended recipient. A single 5 mg depot tablet is enough to cause life-threatening respiratory depression in an opioid-naive child or small adult. Home security is therefore a central element of safe opioid therapy.
- Temperature: Store below 25°C in the original packaging to protect the tablets from moisture and light.
- Security: Keep in a locked cabinet, drawer, or medication safe. Consider a tamper-evident container if visitors or other household members may have access.
- Visibility: Do not leave medication on bedside tables, kitchen counters, or other accessible surfaces.
- Packaging: Retain the original blister foil and carton until use; do not transfer tablets to unlabeled containers.
- Expiry: Do not use tablets after the expiry date printed on the outer packaging.
- Disposal: Return unused, expired, or unwanted tablets to a pharmacy, hospital, or authorized drug take-back program. Do not flush them and do not place them in regular household waste.
- Travel: Keep the medicine in its original packaging during travel, and carry a copy of your prescription. Some countries restrict or prohibit importation of controlled opioids; check regulations before international travel.
Accidental ingestion of even a single Oxycodone Depot Teva GmbH 5 mg tablet can cause fatal respiratory depression in a child or other opioid-naive person. If accidental ingestion is suspected, seek emergency medical help immediately and, if trained and equipped, administer naloxone while awaiting emergency services.
What Does Oxycodone Depot Teva GmbH Contain?
Quick Answer: Each Oxycodone Depot Teva GmbH prolonged-release tablet contains 5 mg of oxycodone hydrochloride as the active substance. Inactive ingredients include components of the sustained-release matrix (typically hypromellose, povidone, and stearic acid), tablet fillers (e.g., lactose monohydrate, magnesium stearate), and a film coating containing titanium dioxide and iron oxide colorants for identification.
Active substance: Oxycodone hydrochloride. Each depot tablet contains 5 mg of oxycodone hydrochloride, equivalent to approximately 4.5 mg of oxycodone base.
Typical Excipients in Prolonged-Release Oxycodone 5 mg
Tablet core: Lactose monohydrate, hypromellose (the release-controlling polymer), povidone, stearic acid, magnesium stearate, and colloidal anhydrous silica. The precise composition may vary slightly between manufacturing batches; always consult the patient information leaflet provided with your specific package for the definitive list.
Oxycodone Depot Teva GmbH tablets contain lactose monohydrate as a filler. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. If you have been told by your doctor that you are intolerant to certain sugars, speak to your doctor before starting treatment.
Tablet coating typically includes polyvinyl alcohol or hypromellose, titanium dioxide (E171) for opacity, macrogol (polyethylene glycol), talc, and iron oxide pigments (E172). For the 5 mg strength, the tablets are commonly blue, round, and biconvex, with a manufacturer-specific marking identifying both strength and producer.
Pack Sizes
Oxycodone Depot Teva GmbH 5 mg is typically supplied in tamper-evident PVC/aluminum blister packs. Standard pack sizes vary by market and regulatory jurisdiction, often including 28, 30, 50, 56, 98, and 100 tablets. Hospital and institutional packs may differ. Always check the packaging you receive against the prescription and speak to the pharmacist if anything is unclear.
The marketing authorization holder for this product is Teva GmbH (Germany), part of the international Teva Pharmaceutical Industries group — one of the world's largest manufacturers of generic and specialty medicines. Teva produces numerous generic opioid analgesics for the European and international markets. Product identity and national trade names may vary; always rely on the package leaflet supplied with your specific pack for authoritative information.
Frequently Asked Questions About Oxycodone Depot Teva GmbH
Oxycodone Depot Teva GmbH is a prolonged-release tablet containing 5 mg of oxycodone hydrochloride, prescribed for moderate to severe pain that can only be adequately managed with opioid analgesics. It is most commonly used for chronic cancer pain, severe palliative care pain, and selected chronic non-cancer pain when other treatments have proven insufficient. The depot formulation delivers oxycodone steadily over 12 hours, making it suitable for around-the-clock background pain control rather than short-term or breakthrough pain.
Oxycodone Depot Teva GmbH uses a prolonged-release matrix that slowly releases the active substance over approximately 12 hours, producing steady plasma concentrations suitable for continuous, long-term pain control. Immediate-release oxycodone, by contrast, is absorbed rapidly and reaches peak effect within about an hour, making it appropriate for short-term acute pain or breakthrough pain episodes. Depot tablets must always be swallowed whole; chewing or crushing them destroys the sustained-release mechanism and can cause a potentially fatal overdose by releasing the full dose at once.
Yes, 5 mg twice daily is one of the lowest commercially available depot doses of oxycodone and is frequently chosen as a starting dose for opioid-naive adults, elderly patients, and those with hepatic or renal impairment. Even at this strength, oxycodone remains a potent Schedule II controlled substance with real risks of respiratory depression, sedation, and dependence. Low initial dosing lets the doctor evaluate tolerability and titrate upward cautiously until adequate analgesia is achieved.
No. Alcohol and oxycodone are both central nervous system depressants, and combining them markedly increases the risk of profound sedation, respiratory depression, loss of consciousness, and death. Alcohol can also accelerate release from the prolonged-release matrix in some formulations, leading to dangerously high peak plasma levels. This prohibition applies to all forms of alcohol — beer, wine, spirits, and alcohol-containing cough syrups or tonics — throughout the duration of therapy.
If you miss a dose of Oxycodone Depot Teva GmbH, take it as soon as you remember, provided that at least 8 hours remain until your next scheduled dose. If less than 8 hours remain, skip the missed dose and resume your regular 12-hour schedule. Never double up to compensate, because this increases the risk of respiratory depression and overdose. Do not take oxycodone more often than every 8 hours under any circumstances, and contact your prescriber if missed doses become frequent.
Like all opioid analgesics, Oxycodone Depot Teva GmbH carries a risk of substance use disorder. Physical dependence and tolerance are expected pharmacological effects of continuous opioid therapy and are not the same as addiction, but repeated use — especially at higher doses or over longer durations — increases the risk of developing an addiction for susceptible individuals. Risk factors include a personal or family history of alcohol or drug misuse, younger age, and untreated mental health conditions. Prescribers should use the lowest effective dose for the shortest necessary duration, reassess at every visit, and screen for misuse. If you are concerned about your use, speak with your healthcare provider.
Therapeutically yes, in the sense that both deliver oxycodone hydrochloride in a prolonged-release oral tablet designed to provide about 12 hours of analgesia. Oxycodone Depot Teva GmbH is a generic version manufactured by Teva GmbH, while OxyContin is the originator brand. Generic medicines are required by regulators to demonstrate bioequivalence to the originator, meaning comparable blood concentrations and clinical effect. Formulation technology, excipients, and tablet appearance may differ, but the active ingredient and therapeutic action are equivalent.
Unused Oxycodone Depot Teva GmbH tablets should never be flushed down the toilet, poured down the sink, or placed in household waste. Because oxycodone is a controlled substance, it must be returned to a pharmacy or an authorized medication take-back program for secure destruction. Many countries also offer national drug take-back days, police collection points, and disposal kits. Prompt return reduces the risk of accidental exposure, diversion, and environmental contamination.
References
- World Health Organization (WHO). WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: WHO; 2018. Available at: who.int
- European Medicines Agency (EMA). Oxycodone Hydrochloride – Summary of Product Characteristics (SmPC) and European Public Assessment Reports. Available at: ema.europa.eu
- U.S. Food and Drug Administration (FDA). Oxycodone Hydrochloride Extended-Release Tablets – Prescribing Information. FDA Approved Drug Products. Available at: fda.gov
- British National Formulary (BNF). Oxycodone hydrochloride monograph. NICE Evidence Services. Available at: bnf.nice.org.uk
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain – United States, 2022. MMWR Recomm Rep. 2022;71(No. RR-3):1–95. DOI: 10.15585/mmwr.rr7103a1
- Chou R, Hartung D, Turner J, et al. Opioid Treatments for Chronic Pain. Comparative Effectiveness Review No. 229. AHRQ Publication No. 20-EHC011. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
- Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–e68. DOI: 10.1016/S1470-2045(12)70040-2
- Busse JW, Craigie S, Juurlink DN, et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017;189(18):E659–E666. DOI: 10.1503/cmaj.170363
- Els C, Jackson TD, Kunyk D, et al. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017;(10):CD012509. DOI: 10.1002/14651858.CD012509.pub2
- Paice JA, Bohlke K, Barton D, et al. Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline. J Clin Oncol. 2023;41(4):914–930. DOI: 10.1200/JCO.22.02198
About Our Medical Editorial Team
This article has been written and medically reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians, clinical pharmacologists, and pharmacists with documented expertise in pain medicine and opioid pharmacology. All medical content is evidence-based and follows current international guidelines from the WHO, EMA, FDA, British National Formulary (BNF), CDC, and major pain medicine societies.
Every article undergoes rigorous review: initial drafting by medical writers, expert review by board-certified physicians, fact-checking against primary sources and regulatory labels, cross-verification with peer-reviewed literature, and scheduled re-review to reflect new evidence and guideline updates.
We apply the GRADE framework for evaluating evidence quality and follow COPE principles for publication ethics. This article is based on Level 1A evidence from systematic reviews, clinical practice guidelines, and authoritative prescribing information. We accept no pharmaceutical company sponsorship or advertising.